welcome to our company page and thank you for your interest in aptinyx inc. aptinyx is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the nmda receptor to enhance pathways involved with nerve cell communication. our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need. at aptinyx, we remain committed and responsive to our employees. we offer an engaging work environment, challenging work assignments, and competitive compensation and benefits. if you are interested in learning more, please visit our website at www.aptinyx.com.
Company profile
Ticker
APTX
Exchange
Website
CEO
Norbert G. Riedel
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
APTX stock data
Latest filings (excl ownership)
25-NSE
Exchange delisting
10 Jul 23
8-K
Departure of Directors or Certain Officers
3 Jul 23
DEF 14A
Definitive proxy
2 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
24 May 23
S-8 POS
Registration of securities for employees (post-effective amendment)
24 May 23
S-8 POS
Registration of securities for employees (post-effective amendment)
24 May 23
S-8 POS
Registration of securities for employees (post-effective amendment)
24 May 23
RW
Registration withdrawal request
24 May 23
PRE 14A
Preliminary proxy
23 May 23
10-Q
2023 Q1
Quarterly report
18 May 23
Transcripts
APTX
Earnings call transcript
2022 Q3
9 Nov 22
APTX
Earnings call transcript
2022 Q2
7 Aug 22
APTX
Earnings call transcript
2022 Q1
13 May 22
APTX
Earnings call transcript
2021 Q4
24 Mar 22
APTX
Earnings call transcript
2021 Q3
10 Nov 21
APTX
Earnings call transcript
2021 Q2
11 Aug 21
APTX
Earnings call transcript
2021 Q1
14 May 21
APTX
Earnings call transcript
2020 Q4
25 Mar 21
APTX
Earnings call transcript
2020 Q3
12 Nov 20
APTX
Earnings call transcript
2020 Q2
13 Aug 20
Latest ownership filings
SC 13D/A
ADAMS STREET PARTNERS LLC
27 Jun 23
SC 13D/A
Longitude Capital Partners II, LLC
16 Mar 23
SC 13D/A
Longitude Capital Partners II, LLC
14 Feb 23
SC 13G/A
Artal International S.C.A.
13 Feb 23
SC 13G/A
Kryzanowski John A
20 Jan 23
4
ASHISH KHANNA
5 Jan 23
4
NORBERT G RIEDEL
5 Jan 23
4
ANDREW KIDD
5 Jan 23
SC 13G/A
Kryzanowski John A
24 Jun 22
SC 13G/A
Kryzanowski John A
24 Jun 22
Financial summary
| Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 44.75 mm | 44.75 mm | 44.75 mm | 44.75 mm | 44.75 mm | 44.75 mm |
| Cash burn (monthly) | 3.88 mm | 4.63 mm | 6.77 mm | 5.29 mm | 3.79 mm | 4.59 mm |
| Cash used (since last report) | 23.26 mm | 27.79 mm | 40.63 mm | 31.75 mm | 22.72 mm | 27.55 mm |
| Cash remaining | 21.49 mm | 16.96 mm | 4.12 mm | 13.01 mm | 22.03 mm | 17.20 mm |
| Runway (months of cash) | 5.5 | 3.7 | 0.6 | 2.5 | 5.8 | 3.7 |
Institutional ownership, Q1 2023
59.4% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 34 |
| Opened positions | 5 |
| Closed positions | 8 |
| Increased positions | 7 |
| Reduced positions | 8 |
| 13F shares | Current |
|---|---|
| Total value | 1.19 bn |
| Total shares | 40.19 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Bain Capital Life Sciences Investors | 8.89 mm | $1.11 mm |
| Bain Capital Life Sciences Fund | 8.07 mm | $24.12 mm |
| Artal International S.C.A. | 6.12 mm | $0.00 |
| Adams Street Partners | 5.40 mm | $649.27 mm |
| New Leaf Ventures III | 3.29 mm | $8.79 mm |
| Frazier Life Sciences VIII | 3.19 mm | $10.27 mm |
| Vanguard | 1.86 mm | $232.25 mm |
| BLK Blackrock | 689.98 k | $86.11 mm |
| Renaissance Technologies | 452.23 k | $56.00 k |
| Acadian Asset Management | 379.33 k | $46.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Jan 23 | Andrew Kidd | Stock Option Common Stock | Grant | Acquire A | No | No | 0.36 | 700,000 | 252.00 k | 700,000 |
| 3 Jan 23 | Riedel Norbert G | Stock Option Common Stock | Grant | Acquire A | No | No | 0.36 | 420,000 | 151.20 k | 420,000 |
| 3 Jan 23 | Ashish Khanna | Stock Option Common Stock | Grant | Acquire A | No | No | 0.36 | 375,000 | 135.00 k | 375,000 |
| 26 May 22 | Henry O Gosebruch | Stock Option Common Stock | Grant | Acquire A | No | No | 0.5 | 40,000 | 20.00 k | 40,000 |
| 26 May 22 | Hombach Robert J. | Stock Option Common Stock | Grant | Acquire A | No | No | 0.5 | 40,000 | 20.00 k | 40,000 |